Table 2.
Antibiotic Use Across 11 701 326 Adult Inpatient Encounters, United States, 2016–2017
| Antibiotic | DOT per 1000 PD | Percentage of Encounters With ≥ 1 DOT (N = 11 701 326) |
|---|---|---|
| Antibiotic class | ||
| All (total) | 869.5 | 64.9 |
| Aminoglycosides | 9.8 | 3.1 |
| β-lactam/β-lactamase inhibitor combinations | 206.4 | 14.5 |
| β-lactam/β-lactamase inhibitor combinations for MDRGNs | 0.5 | 0.03 |
| Carbapenems | 57.8 | 3.9 |
| First- and second-generation cephalosporins | 80.5 | 23.6 |
| Fluoroquinolones | 75.1 | 13.3 |
| Glycopeptides | 113.3 | 19.2 |
| Lincosamides | 38.0 | 4.1 |
| Macrolides | 37.3 | 6.9 |
| Metronidazole | 60.1 | 6.5 |
| Monobactams | 6.0 | 1.0 |
| Oxazolidinones | 6.7 | 0.8 |
| Penicillins | 16.5 | 4.1 |
| Polymyxins | 0.6 | 0.04 |
| Sulfonamides | 9.2 | 1.5 |
| Tetracyclines | 18.3 | 2.6 |
| Third- and fourth-generation cephalosporins | 128.5 | 19.7 |
| Other | 4.9 | 0.6 |
| Spectrum of activity category | ||
| Anti–Bacteroides fragilisa | 220.0 | 25.3 |
| Anti–Clostridioides difficilea | 23.2 | 2.9 |
| Anti-MRSAa | 161.0 | 23.9 |
| Anti–Pseudomonas sppa | 244.8 | 28.5 |
Abbreviations: DOT, days of therapy; MDRGN, multidrug-resistant gram-negative organism; MRSA, methicillin-resistant Staphylococcus aureus; PD, patient-days.
aSee Supplementary Appendix A for lists of agents in each spectrum of activity category.